SLC5A2 and type 2 diabetes mellitus: Recent meta-analyses of randomized controlled trials revealed that SGLT2 inhibitors significantly reduced body weight, BMI, and fat mass with a positive effect but also adversely reduced muscle mass compared with placebo or conventional hypoglycemic therapy in type 2 diabetes patients [3, 4].